Third-Generation Antipsychotics
When psychosis appears — whether from schizophrenia, schizoaffective disorder, bipolar disorder, or another cause — antipsychotic medication is the primary treatment, and third-generation antipsychotics are one of three broad options a psychiatrist might choose from, alongside first- and second-generation agents. The three main third-generation antipsychotics used in psychosis treatment today are aripiprazole, brexpiprazole, and cariprazine, with aripiprazole being the most established and widely prescribed.
What sets this class apart isn't necessarily better effectiveness against psychosis — for the core positive symptoms of psychosis (hallucinations and delusions), third-generation antipsychotics generally perform comparably to second-generation options in clinical trials — but rather a different way of acting on the brain's dopamine system, which translates into a different balance of benefits and side effects.
How They Treat Psychotic Symptoms
Psychosis is strongly linked to overactive dopamine signaling in certain brain pathways. Older antipsychotics treat this by blocking dopamine receptors outright (antagonism). Third-generation antipsychotics instead act as dopamine partial agonists — they occupy the same receptors but only partially activate them, which has the practical effect of dampening dopamine activity when it's too high (as in active psychosis) while avoiding fully shutting it down everywhere in the brain. This is sometimes described as a "dopamine system stabilizer" effect rather than a simple blockade.
In practice, for someone experiencing active psychosis, this means:
Hallucinations and delusions generally improve over a similar timeframe as with other antipsychotics — often showing initial improvement within one to two weeks, with fuller effect over four to six weeks
The medication also affects serotonin receptors (partial agonism at 5-HT1A, antagonism at 5-HT2A in most agents in this class), which may contribute modestly to effects on mood and possibly negative symptoms, alongside the core antipsychotic effect
Effectiveness for Different Symptom Types
Antipsychotics as a whole are most effective against positive symptoms of psychosis (hallucinations, delusions, disorganized thinking) and less reliably effective against negative symptoms (reduced motivation, blunted emotional expression, social withdrawal) or cognitive symptoms (attention, memory, planning difficulties). Third-generation antipsychotics are not an exception to this general pattern, but there's ongoing research interest in whether their distinct mechanism might offer a modest edge for negative symptoms specifically — cariprazine, for instance, has been studied with particular attention to this question given its relatively higher affinity for D3 dopamine receptors. The evidence here is real but still developing, and shouldn't be overstated: these medications are not a breakthrough for negative or cognitive symptoms, just a possible incremental step.
Why a Psychiatrist Might Choose This Class for Psychosis
Common reasons a third-generation antipsychotic might be selected for someone with psychosis include:
Metabolic risk — a person who is overweight, has diabetes or prediabetes, or has a family history of these conditions may benefit from the generally lower metabolic burden of this class compared to options like olanzapine or clozapine.
Prolactin sensitivity — people who've had prolactin-related side effects (menstrual irregularities, sexual dysfunction, breast tissue changes) on other antipsychotics often tolerate this class better, since it tends to raise prolactin less.
Sedation concerns — someone needing to stay alert for work, school, or daily responsibilities might do better on a less sedating option like aripiprazole, compared to more sedating antipsychotics.
Add-on treatment for psychotic depression — aripiprazole and brexpiprazole are both approved as add-on treatments to antidepressants for depression, which can be relevant when psychosis occurs in the context of a severe depressive episode, though additional antipsychotic dosing considerations apply when psychotic features are present.
Long-acting injectable options — aripiprazole is available as a long-acting injectable, which can help with consistent treatment for people who struggle with daily oral medication, particularly relevant in psychotic disorders where poor adherence significantly raises relapse risk.
Important Trade-Offs When Used for Psychosis
Impulse control disorders — this class carries an FDA-flagged risk of new-onset compulsive behaviors (gambling, shopping, eating, hypersexuality), which clinicians and families should watch for, particularly early in treatment or after dose increases. This is a distinctive risk not typically associated with other antipsychotic classes to the same degree.
Akathisia — an inner sense of restlessness or an inability to sit still, which is relatively common with this class and is sometimes mistaken for anxiety or worsening psychiatric symptoms rather than recognized as a medication side effect. It's a common reason people stop taking these medications if it isn't identified and addressed.
Not necessarily better for severe or acute psychosis — in situations involving very severe, acute agitation or a need for rapid sedation (such as in some emergency settings), more sedating antipsychotics are sometimes preferred short-term, with a switch to a less sedating option like a third-generation agent considered later once the acute crisis has passed.
Response isn't guaranteed — as with all antipsychotics, individual response varies significantly, and a person who doesn't respond well to a third-generation antipsychotic may respond better to a different class, and vice versa. This is part of why treatment sometimes involves trying more than one option.
Third-Generation Antipsychotics and Treatment-Resistant Psychosis
For psychosis that hasn't responded to two or more antipsychotic trials, clozapine (a second-generation antipsychotic with unique effectiveness for treatment resistance) generally remains the standard next step rather than a third-generation option, since clozapine has the strongest evidence specifically for treatment-resistant cases. Third-generation antipsychotics are sometimes used as an augmentation strategy alongside another antipsychotic in complex or partially responsive cases, though this approach carries more side-effect risk and less robust evidence than switching to a single, well-matched medication.
Practical Use in Ongoing Psychosis Management
For conditions involving chronic or recurrent psychosis, such as schizophrenia, third-generation antipsychotics are often used for long-term maintenance treatment once an acute episode has stabilized, aimed at preventing relapse. Considerations for long-term use include:
Regular monitoring for movement-related side effects, including akathisia and, less commonly with this class, tardive dyskinesia
Periodic screening for emerging compulsive behaviors
Ongoing assessment of metabolic health (weight, blood sugar, cholesterol), even though risk tends to be lower than with some other antipsychotics
Attention to adherence, with long-acting injectable aripiprazole as one option to support consistent treatment
As with other antipsychotics, stopping treatment — even after symptoms have resolved — is associated with significantly higher relapse risk in chronic psychotic conditions, so decisions about tapering or discontinuing should be made carefully with a psychiatrist rather than done independently.
Third-generation antipsychotics are a genuine, well-established option for treating psychosis, with effectiveness against core psychotic symptoms comparable to other antipsychotic classes.
